Aquestive Therapeutics (NASDAQ:AQST) has completed its Phase 1 dose escalation proof-of-concept study in healthy subjects for AQST-108.
AQST-108 is an oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of anaphylaxis using Aquestive’s proprietary PharmFilm technologies.
Based on the results of this study, Aquestive is in the process of scheduling a pre-IND meeting with FDA.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.